$42.37
Insights on Twist Bioscience Corp
Revenue is up for the last 5 quarters, 54.24M → 71.49M (in $), with an average increase of 6.7% per quarter
Netprofit is up for the last 4 quarters, -59.15M → -43.00M (in $), with an average increase of 11.6% per quarter
In the last 3 years, Twist Bioscience Corp has experienced a drawdown of -56.6%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 55.4%
2.03%
Downside
Day's Volatility :5.36%
Upside
3.4%
72.13%
Downside
52 Weeks Volatility :73.71%
Upside
5.68%
Period | Twist Bioscience Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 6.38% | -0.5% | 0.0% |
6 Months | 156.08% | 13.5% | 0.0% |
1 Year | 227.02% | 8.3% | 1.4% |
3 Years | -55.15% | 16.6% | -19.8% |
Market Capitalization | 2.5B |
Book Value | $9.63 |
Earnings Per Share (EPS) | -3.36 |
Wall Street Target Price | 43.76 |
Profit Margin | -69.24% |
Operating Margin TTM | -64.92% |
Return On Assets TTM | -15.63% |
Return On Equity TTM | -30.4% |
Revenue TTM | 277.5M |
Revenue Per Share TTM | 4.83 |
Quarterly Revenue Growth YOY | 25.1% |
Gross Profit TTM | 84.2M |
EBITDA | -161.2M |
Diluted Eps TTM | -3.36 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.03 |
EPS Estimate Next Year | -2.57 |
EPS Estimate Current Quarter | -0.82 |
EPS Estimate Next Quarter | -0.77 |
What analysts predicted
Upside of 3.28%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 25.4M | ↑ 136.16% |
Net Income | -71.2M | ↑ 20.11% |
Net Profit Margin | -280.16% | ↑ 270.69% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 54.4M | ↑ 113.89% |
Net Income | -107.7M | ↑ 51.14% |
Net Profit Margin | -197.98% | ↑ 82.18% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 90.1M | ↑ 65.67% |
Net Income | -139.9M | ↑ 29.96% |
Net Profit Margin | -155.31% | ↑ 42.67% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 132.3M | ↑ 46.87% |
Net Income | -152.1M | ↑ 8.69% |
Net Profit Margin | -114.94% | ↑ 40.37% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 203.6M | ↑ 53.83% |
Net Income | -217.9M | ↑ 43.24% |
Net Profit Margin | -107.02% | ↑ 7.92% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 245.1M | ↑ 20.41% |
Net Income | -204.6M | ↓ 6.08% |
Net Profit Margin | -83.48% | ↑ 23.54% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 54.2M | ↓ 5.34% |
Net Income | -41.8M | ↓ 18.18% |
Net Profit Margin | -77.1% | ↑ 12.1% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 60.2M | ↑ 10.95% |
Net Income | -59.2M | ↑ 41.44% |
Net Profit Margin | -98.3% | ↓ 21.2% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 63.7M | ↑ 5.92% |
Net Income | -57.4M | ↓ 2.98% |
Net Profit Margin | -90.05% | ↑ 8.25% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 66.9M | ↑ 5.03% |
Net Income | -46.2M | ↓ 19.43% |
Net Profit Margin | -69.08% | ↑ 20.97% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 71.5M | ↑ 6.8% |
Net Income | -43.0M | ↓ 7.0% |
Net Profit Margin | -60.15% | ↑ 8.93% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 75.3M | ↑ 5.32% |
Net Income | -45.5M | ↑ 5.78% |
Net Profit Margin | -60.41% | ↓ 0.26% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 115.8M | ↑ 35.18% |
Total Liabilities | 317.2M | ↑ 44.84% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 187.0M | ↑ 61.49% |
Total Liabilities | 34.9M | ↓ 88.99% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 398.9M | ↑ 113.31% |
Total Liabilities | 62.6M | ↑ 79.37% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 702.1M | ↑ 76.02% |
Total Liabilities | 121.3M | ↑ 93.67% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 961.4M | ↑ 36.93% |
Total Liabilities | 172.0M | ↑ 41.82% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 776.4M | ↓ 19.24% |
Total Liabilities | 153.0M | ↓ 11.06% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 910.0M | ↓ 5.35% |
Total Liabilities | 163.6M | ↓ 4.85% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 853.9M | ↓ 6.16% |
Total Liabilities | 150.0M | ↓ 8.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 810.3M | ↓ 5.1% |
Total Liabilities | 152.8M | ↑ 1.86% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 776.4M | ↓ 4.19% |
Total Liabilities | 153.0M | ↑ 0.12% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 732.8M | ↓ 5.61% |
Total Liabilities | 142.8M | ↓ 6.67% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 702.8M | ↓ 4.09% |
Total Liabilities | 142.7M | ↓ 0.04% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -66.2M | ↑ 28.97% |
Investing Cash Flow | 27.3M | ↓ 373.33% |
Financing Cash Flow | 88.8M | ↑ 39.22% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -87.9M | ↑ 32.91% |
Investing Cash Flow | -104.8M | ↓ 483.84% |
Financing Cash Flow | 158.6M | ↑ 78.53% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -142.3M | ↑ 61.77% |
Investing Cash Flow | -114.7M | ↑ 9.39% |
Financing Cash Flow | 303.7M | ↑ 91.53% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -112.2M | ↓ 21.1% |
Investing Cash Flow | 156.2M | ↓ 236.2% |
Financing Cash Flow | 329.2M | ↑ 8.38% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -124.4M | ↑ 10.82% |
Investing Cash Flow | -232.9M | ↓ 249.17% |
Financing Cash Flow | 270.5M | ↓ 17.82% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -54.1M | ↑ 4167.56% |
Investing Cash Flow | -7.0M | ↓ 350.49% |
Financing Cash Flow | -395.0K | ↓ 131.85% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -44.3M | ↓ 18.09% |
Investing Cash Flow | 41.2M | ↓ 690.45% |
Financing Cash Flow | 1.5M | ↓ 486.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -23.4M | ↓ 47.14% |
Investing Cash Flow | 18.7M | ↓ 54.64% |
Financing Cash Flow | -661.0K | ↓ 143.34% |
Sell
Neutral
Buy
Twist Bioscience Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Twist Bioscience Corp | 35.59% | 156.08% | 227.02% | -55.15% | 95.74% |
Idexx Laboratories, Inc. | -0.45% | 15.83% | 2.89% | -5.18% | 106.42% |
Agilent Technologies Inc. | 0.68% | 33.81% | 13.34% | 10.06% | 88.25% |
Thermo Fisher Scientific, Inc. | 0.58% | 33.22% | 11.94% | 27.81% | 121.36% |
Danaher Corp. | 3.05% | 27.63% | 8.93% | -2.93% | 94.21% |
Iqvia Holdings Inc. | -1.66% | 16.95% | 23.28% | -0.99% | 76.96% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Twist Bioscience Corp | NA | NA | NA | -3.03 | -0.3 | -0.16 | NA | 9.63 |
Idexx Laboratories, Inc. | 49.03 | 49.03 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 32.89 | 32.89 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 37.35 | 37.35 | 2.81 | 21.53 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 45.86 | 45.86 | 3.13 | 7.63 | 0.08 | 0.04 | 0.0 | 72.16 |
Iqvia Holdings Inc. | 32.18 | 32.18 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Twist Bioscience Corp | Buy | $2.5B | 95.74% | NA | -69.24% |
Idexx Laboratories, Inc. | Buy | $41.1B | 106.42% | 49.03 | 23.08% |
Agilent Technologies Inc. | Buy | $40.8B | 88.25% | 32.89 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $220.4B | 121.36% | 37.35 | 13.99% |
Danaher Corp. | Buy | $185.5B | 94.21% | 45.86 | 18.55% |
Iqvia Holdings Inc. | Buy | $42.8B | 76.96% | 32.18 | 9.06% |
ARK Investment Management LLC
BlackRock Inc
Vanguard Group Inc
JPMorgan Chase & Co
Artisan Partners Limited Partnership
Nikko Asset Management Americas Inc
Twist Bioscience Corp’s price-to-earnings ratio stands at None
Read Moreat twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
Organization | Twist Bioscience Corp |
Employees | 919 |
CEO | Dr. Emily Marine Leproust Ph.D. |
Industry | Health Technology |